Our live webinar on what the new ‘normal’ means for oncology in the wake of COVID-19 can now be watched on demand. Our expert panel discussed the COVID-19 situation in Europe and Australia, how oncologists and their patients have adapted to the situation and what the enduring impact will be on medical oncology.
Professor Eva Segelov, Professor/Director of Oncology at Monash Health and Monash University. Board Member, Australasian Gastrointestinal Trials Group. Co-Founder, Commonwealth Neuroendocrine Tumour Collaboration.
Professor Hans Prenen, Deputy Head of the Oncology Department, University Hospital Antwerp Belgium. Head of Phase I – Early Clinical Trials Unit; Director of Clinical Trial Management Program.
Associate Professor Nick Pavlakis, Senior Staff Specialist, Department of Medical Oncology, Royal North Shore Hospital, Sydney. President, Australasian Lung Cancer Trials Group. President, The Clinical Oncology Society of Australia.
Associate Professor Nicholas Wilcken, Director of Medical Oncology, Westmead Hospital, Sydney. Associate Professor of Medicine, University of Sydney.
Professor Raina MacIntyre, Head, Biosecurity Research Program, Kirby Institute, UNSW Medicine. Professor of Global Biosecurity & NHMRC Principal Research Fellow.
the limbic · Navigating the new ‘normal’ for oncology in the era of COVID-19